secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001477932-24-002772
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q1 revenue $170k (+15% YoY); cash $11.8M; targets $10M annual cost cuts for 2025 cash flow neutrality
--------------------------------------------------------------------------------

- Q1 2024 revenue ~$170,000, up 15% YoY; cash and equivalents $11.8M as of March 31, 2024.
- Targeting $10M in annualized cost reductions; aiming for cash flow neutrality in 2025 via non-dilutive funding, revenue growth, and milestone payments.
- Applied for $25M in U.S. and $18M in European non-dilutive grants.
- Expects substantial Nu.Q NETs and Capture-PCR clinical data by end of June; then laser focus on commercialization.
- Volition Vet revenue expected to accelerate in H2 2024 after recent Antech and Fujifilm product launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793224002772/0001477932-24-002772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793224002772/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-002772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer